233 related articles for article (PubMed ID: 32369815)
1. Update on C3 Glomerulopathy: A Complement-Mediated Disease.
Caravaca-Fontán F; Lucientes L; Cavero T; Praga M
Nephron; 2020; 144(6):272-280. PubMed ID: 32369815
[TBL] [Abstract][Full Text] [Related]
2. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
3. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
Caravaca-Fontán F; Díaz-Encarnación MM; Lucientes L; Cavero T; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez A; Pérez de José A; Rabasco C; Rodado R; Fernández L; Pérez Gómez V; Ávila AI; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Rodríguez E; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; Cano-Megías M; González F; Shabaka A; López-Rubio ME; Fenollosa MÁ; Martín-Penagos L; Da Silva I; Alonso Titos J; Rodríguez de Córdoba S; Goicoechea de Jorge E; Praga M;
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1287-1298. PubMed ID: 32816888
[TBL] [Abstract][Full Text] [Related]
5. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
6. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
7. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
Front Immunol; 2018; 9():2260. PubMed ID: 30333829
[TBL] [Abstract][Full Text] [Related]
8. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
9. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
10. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
11. C3G and Ig-MPGN-treatment standard.
Noris M; Remuzzi G
Nephrol Dial Transplant; 2024 Jan; 39(2):202-214. PubMed ID: 37604793
[TBL] [Abstract][Full Text] [Related]
12. Treating C3 glomerulopathy with eculizumab.
Welte T; Arnold F; Kappes J; Seidl M; Häffner K; Bergmann C; Walz G; Neumann-Haefelin E
BMC Nephrol; 2018 Jan; 19(1):7. PubMed ID: 29329521
[TBL] [Abstract][Full Text] [Related]
13. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
15. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
16. Complement inhibition in C3 glomerulopathy.
Nester CM; Smith RJ
Semin Immunol; 2016 Jun; 28(3):241-9. PubMed ID: 27402056
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
19. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
Hohenstein B; Amann K; Menne J
Internist (Berl); 2019 May; 60(5):458-467. PubMed ID: 30859280
[TBL] [Abstract][Full Text] [Related]
20. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
